SM-13496

DRUG3 trials

Sponsors

Sumitomo Pharma Co., Ltd.

Conditions

Bipolar DepressionBipolar I DisorderSchizophrenia

Phase 3

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

CompletedNCT01614912

Sumitomo Pharma Co., Ltd.Schizophrenia

Start: 2012-08-31End: 2015-05-31Updated: 2022-04-12

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

CompletedNCT01986114

Sumitomo Pharma Co., Ltd.Bipolar I Disorder

Start: 2014-01-29End: 2018-02-17Updated: 2022-04-12

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

CompletedNCT01986101

Sumitomo Pharma Co., Ltd.Bipolar Depression

Start: 2014-02-19End: 2017-02-16Updated: 2022-04-12

Related Papers

A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression.

2024-08-031 citations

Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study.

2021-08-026 citations

Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study

Journal of Affective Disorders2020-12-088 citations